Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 325-331

  Yamaguchi, Shinichi ^a   Inada, Chifumi ^a   Tamura, Mitsutaka ^a   Sato, Nahoko ^a   Yamada, Masateru ^a   Itaba, Shoichi ^a   Okazaki, Seiji ^a   Matsuura, Hirotoshi ^a   Fujii, Shigeo ^a   Matsuda, Fuko ^a   Goto, Yasufumi ^a   Mochizuki, Hidenori ^a   Kurumatani, Hajimu ^a   Miyamoto, Mitsuko ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

5 6 nephrectomized; Anti glomerular basement membrane; Beraprost sodium; Chronic kidney disease; Endothelial cell protection; Glomerulonephritis; Indoxyl sulfate; Survival rate; Uremic toxin

Indexed keywords

BERAPROST; CREATININE; INDICAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGLOMERULAR BASEMENT MEMBRANE GLOMERULONEPHRITIS; AORTA; ARTICLE; CELL DAMAGE; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIUM CELL; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

5/6 NEPHRECTOMIZED; ANTI-GLOMERULAR BASEMENT MEMBRANE GLOMERULONEPHRITIS; BERAPROST SODIUM; CHRONIC KIDNEY DISEASE; ENDOTHELIAL CELL PROTECTION; INDOXYL SULFATE; SURVIVAL RATE; UREMIC TOXIN;

ANIMALS; AORTA; CYCLIC AMP; ENDOTHELIAL CELLS; EPOPROSTENOL; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; HUMANS; INDICAN; MALE; NEPHRECTOMY; RATS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS;

EID: 84885419046     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.07.032     Document Type: Article

References (26)

1. Adelibieke, Y., Shimizu, H., Muteliefu, G., Bolati, D., Niwa, T., 2012. Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity. Journal of Renal Nutrition 22, 86-89.
2. Barreto, F.C., Barreto, D.V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z.A., European Uremic Toxin Work Group (EUTox), 2009. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical Journal of the American Society of Nephrology 4, 1551-1558.
3. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S., RENAAL Study Investigators, 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 345, 861-869.
4. Calaf, R., Cerini, C., Génovésio, C., Verhaeghe, P., Jourde-Chiche, N., Bergé-Lefranc, D., Gondouin, B., Dou, L., Morange, S., Argilés, A., Rathelot, P., Dignat-George, F., Brunet, P., Charpiot, P., 2011. Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. Journal of Chromato-graphy B 879, 2281-2286.
5. Chiang, C.K., Tanaka, T., Inagi, R., Fujita, T., Nangaku, M., 2011. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Laboratory Investigation 91, 1564-1571.
6. Davignon, J., Ganz, P., 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109, III27-III32. (Pubitemid 38786440)
7. Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., Berland, Y., Brunet, P., 2004. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International 65, 442-451. (Pubitemid 38130638)
8. Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, F., Brunet, P., 2007. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and Haemostasis 5, 1302-1308. (Pubitemid 46902134)
9. El Nahas, A.M., Bello, A.K., 2005. Chronic kidney disease: the global challenge. Lancet 365, 331-340. (Pubitemid 40139112)
10. Kawakami, T., Inagi, R., Wada, T., Tanaka, T., Fujita, T., Nangaku, M., 2010. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. American Journal of Physiology-Renal Physiology 299, F568-F576.
11. Krakower, C.A., Nicholes, B.K., Greenspon, S.A., 1978. Proteinuria and the fragility of normal and diseased glomerular basement membrane. Proceedings of the Society for Experimental Biology and Medicine 159, 324-334. (Pubitemid 9152532)
12. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I., Collaborative Study Group, 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345, 851-860.
13. 2 analogue, for intermittent claudication: a doubleblind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 102, 426-431. (Pubitemid 30490681)
14. Mann, J.F., Schmieder, R.E., Dyal, L., McQueen, M.J., Schumacher, H., Pogue, J., Wang, X., Probstfield, J.L., Avezum, A., Cardona-Munoz, E., Dagenais, G.R., Diaz, R., Fodor, G., Maillon, J.M., Rydén, L., Yu, C.M., Teo, K.K., Yusuf, S., TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators, 2009. Effect of telmisartan on renal outcomes: a randomized trial. Annals of Internal Medicine 151, 1-10.
15. Maschio, G., Alberti, D., Locatelli, F., Mann, J.F., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., Zucchelli, P., 1999. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE inhibition in progressive renal insufficiency (aipri) study group. Journal of Cardiovascular Pharmacology 33, S16-S20.
16. Mitch, W.E., Walser, M., Buffington, G.A., Lemann Jr., J., 1976. A simple method of estimating progression of chronic renal failure. Lancet 18, 1326-1328.
17. Miyazaki, T., Aoyama, I., Ise, M., Seo, H., Niwa, T., 2000. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrology Dialysis Transplantation 15, 1773-1781.
18. Nagaya, N., Uematsu, M., Okano, Y., Satoh, T., Kyotani, S., Sakamaki, F., Nakanishi, N., Miyatake, K., Kunieda, T., 1999. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Journal of the American College of Cardiology 34, 1188-1192. (Pubitemid 29500559)
19. National Kidney Foundation, 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 39, S1-266.
20. Niwano, K., Arai, M., Koitabashi, N., Hara, S., Watanabe, A., Sekiguchi, K., Tanaka, T., Iso, T., Kurabayashi, M., 2006. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arteriosclerosis Thrombosis and Vascular Biology 26, 1036-1042. (Pubitemid 43732109)
21. Palm, F., Nangaku, M., Fasching, A., Tanaka, T., Nordquist, L., Hansell, P., Kawakami, T., Nishijima, F., Fujita, T., 2010. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. American Journal of Physiology - Renal Physiology 299, F380-F386.
22. Tamura, Y., Kosuga, M., Yamashita, M., Tomioka, S., Sasaki, M., Hikita, T., Nakajima, H., Kojima, K., Uchida, S., 2008. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clinical and Experimental Nephrology 12, 256-263.
23. Ueda, H., Shibahara, N., Takagi, S., Inoue, T., Katsuoka, Y., 2007. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Therapeutic Apheresis and Dialysis 11, 189-195. (Pubitemid 46716161)
24. Vanholder, R., De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P.P., Deppisch, R., Descamps-Latscha, B., Henle, T., Jörres, A., Lemke, H.D., Massy, Z.A., Passlick-Deetjen, J., Rodriguez, M., Stegmayr, B., Stenvinkel, P., Tetta, C., Wanner, C., Zidek, W., European Uremic Toxin Work Group (EUTox), 2003. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney International 63, 1934-1943. (Pubitemid 36513344)
25. Wright Jr., T., Bakris, G., Greene, T., Agodoa, L.Y., Appel, L.J., Charleston, J., Cheek, D., Douglas-Baltimore, J.G., Gassman, J., Glassock, R., Hebert, L., Jamerson, K., Lewis, J., Phillips, R.A., Toto, R.D., Middleton, J.P., Rostand, S.G., African American Study of Kidney Disease and Hypertension Study Group, 2002. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 288;, pp. 2421-2431. (Pubitemid 35340538)
26. Yamada, M., Sasaki, R., Sato, N., Suzuki, M., Tamura, M., Matsushita, T., Kurumatani, H., 2002. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. European Journal of Pharmacology 449, 167-176.